Haemonetics Corporation (NYSE: HAE) is a Healthcare company (Medical - Devices) with a market capitalization of $5.5B. The Maz Rating grades it against the other companies in its sector.
Haemonetics Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $120.92, Haemonetics Corporation trades at 53.2x trailing earnings, 4.0x sales and 6.1x book value, with an EV/EBITDA of 23.0. Over the last twelve months it generated about $1.4B of revenue and $104M of net income. It runs a gross margin of 58.8%, an operating margin of 18.3% and a net margin of 7.5%. It shows return on equity of 12.1%, return on invested capital of 8.8% and a free cash flow yield of 5.5%. On the balance sheet: a debt-to-equity ratio of 1.25 and a current ratio of 2.84. Over the past 52 weeks the share price ranged from $51.00 to $132.00, with a beta of 0.54.
Haemonetics Corporation does not currently pay a dividend.
21 Wall Street analyst ratings cover the stock: 12 Buy and 9 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.